Freedom Biosciences
Wednesday, June 05, 2024
CNS/Neurological
Company Presentation Theater 4
Freedom Biosciences is a Yale spin-out and clinical-stage biotech platform developing next gen neuropsych combo drugs. The company's lead program for Treatment Resistant Depression is ~18 months from a major inflection point - the readout of Phase 2a (n=120). The company is co-founded by the Chair of Psychiatry at Yale and run by the top biotech execs from Johnson & Johnson and Biohaven (acquired $11.6b by Pfizer).
The lead program (Free001 “extended efficacy” ketamine) showed 3x longer duration of antidepressant effect than ketamine & esketamine: 14-21 days in antidepressant effects vs. 2-7 days for ketamine and esketamine SPRAVATO.
Free001 is positioned to build upon the success of Jannsen’s Esketamine SPRAVATO, which is $1B+ ARR drug and the fastest growing program in Jannsen’s portfolio, which is now approved 80+ markets, including China.
Company Website:
http://www.freedombio.co
Lead Product in Development:
The lead program (Free001 “extended efficacy” ketamine) is entering Phase 2a (n=120) in Q2 2024. In PoC study at Yale, Free001 combination showed 3x longer duration of antidepressant effect than ketamine & esketamine: 14-21 days in antidepressant effects vs. 2-7 days for racemic ketamine and esketamine.
Free001 is positioned to build upon the success of Jannsen’s Esketamine SPRAVATO, which is $1B+ ARR drug and the fastest growing program in Jannsen’s portfolio, which is now approved 80+ markets, including China.
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Company HQ City
Tiburon
Company HQ State
CA
Company HQ Country
United States
CEO/Top Company Official
Dina Burkitbayeva
Development Phase of Primary Product
Phase II
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())